| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Loureirin D does not have a single well-defined molecular target. It exhibits multiple pharmacological activities, suggesting interactions with various targets and pathways. It has demonstrated antibacterial activity against Helicobacter pylori with a MIC of 111,100.0 nM. It also shows significant inhibitory effects on influenza A virus and HIV-1 virus. The compound's anti-inflammatory activity may involve suppression of proinflammatory signaling pathways, while its anticoagulant activity suggests effects on platelet aggregation and vascular relaxation.
|
|---|---|
| ln Vitro |
In vitro, loureirin D exhibits antibacterial activity against Helicobacter pylori ATCC 43504 with a MIC of 111,100.0 nM. It also shows significant inhibitory effects on influenza A virus and HIV-1 virus. The compound displays antitumor activity, cardioprotective effects, anti-inflammatory effects, and antioxidative activity in various in vitro models. These activities suggest that loureirin D is a multitargeted natural product with potential for treating multiple disease conditions.
|
| ln Vivo |
In vivo, loureirin D has demonstrated antithrombotic activity in two independent preclinical models. The compound also exhibits anti-inflammatory, analgesic, and wound healing properties in vivo. Its cardioprotective effects and ability to promote blood circulation have been noted. However, detailed in vivo efficacy data are limited in publicly available sources, and the compound is not approved for clinical use.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for loureirin D would typically involve screening against a panel of targets to identify its molecular interactions. Given its anti-inflammatory activity, assays for COX-1/COX-2 inhibition, LOX inhibition, or NF-κB activity would be relevant. For antiviral activity, assays for viral protease, polymerase, or entry inhibition could be used. Antibacterial activity could be assessed using enzyme inhibition assays targeting bacterial cell wall synthesis or other essential bacterial processes. Binding to platelet aggregation targets could also be evaluated.
|
| Cell Assay |
In vitro cell-based assays for loureirin D involve culturing appropriate cell lines (e.g., cancer cells, macrophages, virus-infected cells) and treating them with the compound to assess effects on cell viability, inflammation, or infection. Cytotoxicity is evaluated using MTT or CellTiter-Glo assays. Anti-inflammatory activity is assessed by measuring cytokine production in LPS-stimulated macrophages. Antiviral activity is assessed by measuring viral replication in infected cells. Antibacterial activity is assessed using broth microdilution or agar dilution methods to determine MICs.
|
| Animal Protocol |
In vivo animal studies for loureirin D have been conducted in preclinical models of thrombosis, demonstrating antithrombotic activity. Studies on anti-inflammatory, analgesic, and wound healing effects have also been reported. Typical protocols would involve oral or intraperitoneal administration of loureirin D in rodents at various doses, with endpoints including thrombosis parameters, inflammation markers, pain responses, or wound healing measurements. No standardized protocol is available.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of loureirin D have not been extensively characterized. As a dihydrochalcone with a molecular weight of 288.30 and multiple hydroxyl groups, it is expected to have moderate oral bioavailability. The compound would likely undergo extensive metabolism, including glucuronidation and sulfation of phenolic hydroxyl groups. No specific PK parameters such as half-life, Cmax, or bioavailability are available from publicly accessible sources.
|
| Toxicity/Toxicokinetics |
The toxicity profile of loureirin D has not been systematically evaluated. As a natural product used in traditional medicine, it may have a favorable safety profile, but this has not been confirmed in controlled toxicology studies. Standard toxicology assessments would include acute and sub-chronic toxicity studies in rodents, with endpoints including clinical signs, body weight, clinical pathology, and histopathology. No specific toxicity data are available.
|
| References | |
| Additional Infomation |
It has been reported that the dragon blood tree (Dracaena cochinchinensis) contains Loureirin D, and there is relevant data available.
Loureirin D is a dihydrochalcone natural product isolated from Dracaena cochinchinensis (Dragon's Blood). It has the molecular formula C16H16O5 and a molecular weight of 288.30. The compound exhibits anti-inflammatory, antioxidant, anticoagulant, anti-tumor, cardioprotective, and antiviral properties. It has been used in traditional Chinese medicine for centuries. Loureirin D is not approved for clinical use and is available only for research purposes. |
| Molecular Formula |
C16H16O5
|
|---|---|
| Molecular Weight |
288.30
|
| Exact Mass |
288.099
|
| CAS # |
119425-91-1
|
| PubChem CID |
13939318
|
| Appearance |
White to pink solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
540.9±38.0 °C at 760 mmHg
|
| Flash Point |
203.5±20.3 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.634
|
| LogP |
2.29
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
21
|
| Complexity |
338
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])[H])C1=C([H])C(=C([H])C(=C1C([H])([H])C([H])([H])C(C1C([H])=C([H])C(=C([H])C=1[H])O[H])=O)O[H])O[H]
|
| InChi Key |
AQMBVNGTZRFEPF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H16O5/c1-21-16-9-12(18)8-15(20)13(16)6-7-14(19)10-2-4-11(17)5-3-10/h2-5,8-9,17-18,20H,6-7H2,1H3
|
| Chemical Name |
3-(2,4-dihydroxy-6-methoxyphenyl)-1-(4-hydroxyphenyl)propan-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4686 mL | 17.3430 mL | 34.6861 mL | |
| 5 mM | 0.6937 mL | 3.4686 mL | 6.9372 mL | |
| 10 mM | 0.3469 mL | 1.7343 mL | 3.4686 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
